Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
EOCN Catalyst Timeline
Dated clinical, regulatory and corporate events for Eocene Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Eocene Ltd.
Upcoming catalysts 2
Event history 3
Past FDA Catalysts and PDUFA Decisions
How EOCN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aramchol Small MoleculesCompletedNCT04480827 | Hepatic Impairment | Phase 1 | COMPLETED | 57 | Mar 24, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every EOCN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in EOCN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in EOCN for Q3 2026. | ||||
Ownership Trends
EOCN Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How EOCN ranks across every disease it competes in
EOCN News
Eocene and Barcode Nanotech Report Progress in the Development of Tumor Microenvironment-Targeted Lipid Nanoparticles Formulation of Aramchol
Eocene Ltd. reported progress in developing a novel lipid nanoparticle formulation of Aramchol, targeting the tumor microenvironment in liver and GI tumors. This formulation aims to improve the efficacy of immunotherapy and standard treatments by addressing fibrosis. The collaboration with Barcode Nanotech enhances the delivery and effectiveness of Aramchol in cancer therapies.
Read more →Eocene Announces its First European Sales and Distribution Agreement to Accelerate the Commercialization of Colospan's CG-100 Device
Eocene Ltd. announced a distribution agreement for its CG-100 device with Hospital Line SA, granting exclusive rights in Greece and Cyprus. This partnership aims to enhance CG-100's commercial presence in Europe, coinciding with an ongoing U.S. pivotal study. The launch is set to occur at the upcoming 17th Hellenic-Cypriot Surgical Conference.
Read more →